Literature DB >> 20226527

FISH analysis of circulating CD34+ cells as a new tool for genetic monitoring in MDS: verification of the method and application to 27 MDS patients.

Friederike Braulke1, Julie Schanz, Klaus Jung, Katayoon Shirneshan, Kristina Schulte, Claudia Schuetze, Rainer Steffens, Lorenz Trümper, Detlef Haase.   

Abstract

In myelodysplastic syndromes (MDS) chromosomal anomalies can be identified in 50-80% of patients. They have a diagnostic and prognostic impact and are increasingly considered for therapeutic decisions. Cytomorphology and cytogenetic analyses of bone marrow (bm) cells define the goldstandard to diagnose MDS patients and to document treatment response. We present a novel method using peripheral blood (pb) for frequent cytogenetic monitoring: after immunomagnetic cell separation circulating CD34+ cells were analysed by fluorescence in situ hybridization (FISH). We compared FISH analyses of enriched and non-enriched pb and bm cells with conventional chromosome banding analyses of bm metaphases: analysing circulating CD34+ cells by FISH is a sensitive, reliable method to measure the abnormal cell clones in pb. This method is practicable, non-invasive, representative for the clonal situation in the bm, and has a predictive value. Its feasibility was proven in a cohort of 27 MDS patients. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20226527     DOI: 10.1016/j.leukres.2010.01.010

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  9 in total

1.  Higher Level of Peripheral Blood CD34 Positive Cells Presented with Unfavorable Prognosis in Intermediate-Low Risk Acute Promyelocytic Leukemia.

Authors:  Cuiling Zhang; Haibo Dong; Yipeng Lin; Peipei Xu; Rongfu Zhou; Hui Zeng
Journal:  Indian J Hematol Blood Transfus       Date:  2019-12-17       Impact factor: 0.900

2.  Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group.

Authors:  Friederike Braulke; Uwe Platzbecker; Catharina Müller-Thomas; Katharina Götze; Ulrich Germing; Tim H Brümmendorf; Florian Nolte; Wolf-Karsten Hofmann; Aristoteles A N Giagounidis; Michael Lübbert; Peter L Greenberg; John M Bennett; Francesc Solé; Mar Mallo; Marilyn L Slovak; Kazuma Ohyashiki; Michelle M Le Beau; Heinz Tüchler; Michael Pfeilstöcker; Thomas Nösslinger; Barbara Hildebrandt; Katayoon Shirneshan; Carlo Aul; Reinhard Stauder; Wolfgang R Sperr; Peter Valent; Christa Fonatsch; Lorenz Trümper; Detlef Haase; Julie Schanz
Journal:  Haematologica       Date:  2014-10-24       Impact factor: 9.941

Review 3.  Myelodysplastic syndromes: diagnosis, prognosis, and treatment.

Authors:  Ulrich Germing; Guido Kobbe; Rainer Haas; Norbert Gattermann
Journal:  Dtsch Arztebl Int       Date:  2013-11-15       Impact factor: 5.594

4.  Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid.

Authors:  Andrea Kuendgen; Gesine Bug; Oliver G Ottmann; Detlef Haase; Julie Schanz; Barbara Hildebrandt; Kathrin Nachtkamp; Judith Neukirchen; Ariane Dienst; Rainer Haas; Ulrich Germing; Norbert Gattermann
Journal:  Clin Epigenetics       Date:  2011-04-08       Impact factor: 6.551

5.  Clonal architecture of del(5q) myelodysplastic syndromes: aberrant CD5 or CD7 expression within the myeloid progenitor compartment defines a subset with high clonal burden.

Authors:  U Oelschlaegel; M Alexander Röhnert; B Mohr; K Sockel; S Herold; G Ehninger; M Bornhäuser; C Thiede; U Platzbecker
Journal:  Leukemia       Date:  2015-06-24       Impact factor: 11.528

6.  Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA.

Authors:  Johann-Christoph Jann; Daniel Nowak; Florian Nolte; Stephanie Fey; Verena Nowak; Julia Obländer; Jovita Pressler; Iris Palme; Christina Xanthopoulos; Alice Fabarius; Uwe Platzbecker; Aristoteles Giagounidis; Katharina Götze; Anne Letsch; Detlef Haase; Richard Schlenk; Gesine Bug; Michael Lübbert; Arnold Ganser; Ulrich Germing; Claudia Haferlach; Wolf-Karsten Hofmann; Maximilian Mossner
Journal:  J Med Genet       Date:  2017-06-09       Impact factor: 6.318

7.  Targeted deep sequencing of CD34+ cells from peripheral blood can reproduce bone marrow molecular profile in myelodysplastic syndromes.

Authors:  Roman Martin; Pamela Acha; Christina Ganster; Laura Palomo; Sascha Dierks; Francisco Fuster-Tormo; Mar Mallo; Vera Ademà; Paula Gómez-Marzo; Nuri De Haro; Neus Solanes; Lurdes Zamora; Blanca Xicoy; Katayoon Shirneshan; Johanna Flach; Friederike Braulke; Julie Schanz; Arkadiusz Kominowski; Martin Stromburg; Alina Brockmann; Lorenz Trümper; Francesc Solé; Detlef Haase
Journal:  Am J Hematol       Date:  2018-04-10       Impact factor: 10.047

8.  Deep sequencing in CD34+ cells from peripheral blood enables sensitive detection of measurable residual disease in AML.

Authors:  Sebastian Stasik; Clara Burkhard-Meier; Michael Kramer; Jan M Middeke; Uta Oelschlaegel; Katja Sockel; Gerhard Ehninger; Hubert Serve; Carsten Müller-Tidow; Claudia D Baldus; Christoph Röllig; Martin Bornhäuser; Uwe Platzbecker; Christian Thiede
Journal:  Blood Adv       Date:  2022-06-14

Review 9.  Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes.

Authors:  Aristoteles Giagounidis; Ghulam J Mufti; Pierre Fenaux; Ulrich Germing; Alan List; Kyle J MacBeth
Journal:  Ann Hematol       Date:  2013-09-10       Impact factor: 3.673

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.